LONGITUDINAL CHANGE IN 99mTcHMPAO CEREBRAL PERFUSION SPECT IN PARKINSON’S DISEASE OVER ONE YEAR

M J Firbank, S Molloy, I G McKeith, D J Burn, J T O’Brien

**Background:** Brain perfusion deficits have been reported previously in subjects with Parkinson’s disease in comparison with healthy controls.

**Objective:** To carry out a longitudinal study of perfusion in patients with Parkinson’s disease and controls to find areas showing a reduction in perfusion over one year.

**Methods:** Two HMPAO cerebral perfusion scans were acquired one year apart in 30 subjects with Parkinson’s disease (mean (SD) age, 76 (5) years) and 34 healthy comparison subjects (76 (7) years). Scans were normalised to the mean intensity in the cerebellum.

**Results:** Using SPM99 within groups to investigate regions that showed a decrease in perfusion between scans, it was found that in Parkinson’s disease subjects but not controls there was a significant cluster in the frontal lobe (Brodmann area 10) where perfusion decreased over the year.

**Conclusions:** The progressive frontal perfusion deficits in Parkinson’s disease are consistent with results from previous structural and neuropsychological studies suggesting frontal lobe involvement and executive dysfunction even in early Parkinson’s disease.

**METHODS**

**Subjects**

We recruited 38 subjects with Parkinson’s disease from a community dwelling population of patients referred to geographically based neurology services. Diagnosis was made by consensus between experienced clinicians who were blind to the single photon computed emission tomography (SPECT) results, using the UK Parkinson’s Disease Society brain bank criteria for Parkinson’s disease. Thirty-nine normal subjects were recruited from among friends and spouses of patients. Subjects with evidence of stroke, significant cognitive decline, or dementia (either from the history or from the presence of focal neurology or cognitive impairment on examination) were excluded from the study. All subjects underwent SPECT cerebral perfusion scans at recruitment, and again after one year. Eight of the parkinsonian subjects and five of the normal subjects refused a repeat SPECT scan, and all the data presented here are from the 30 parkinsonian and 34 normal subjects who were rescaned.

At baseline 21 of the 30 parkinsonian subjects were taking levodopa (mean (SD) dose, 462 (338) mg). This increased to 2711 after one year (mean dose 499 (288) mg). No other antiparkinsonian drugs were being used. Treatment was not stopped for scanning. Two control and five parkinsonian subjects were taking antidepressant drugs.

The study was approved by the local research ethics committee and UK Department of Health’s Administration of Radioactive Substances Advisory Committee (ARSAC). All participants gave their informed written consent.

Subjects underwent detailed physical, neurological, and neuropsychiatric examinations, which included history, mental state, and physical examination. Standardised schedules administered included the mini-mental state examination (MMSE), the Cambridge cognitive examination (CAMCOG), the geriatric depression (15 item) scale (GDS), and the unified Parkinson’s disease rating scale motor subsection (UPDRS III). Data from the subjects studied here have been included in other reports.

**SPECT data acquisition**

Data acquisition was as previously described. Briefly, subjects were imaged approximately 10 minutes after a bolus intravenous injection of 500 MBq of 99mTc-HMPAO (Ceretec, GE-Healthcare, UK). Images were reconstructed with a pixel size of 3.54×3.54×3.54 mm.

**Abbreviations:** CAMCOG, Cambridge cognitive examination; GDS, geriatric depression (15 item) scale; HMPAO, hexamethylpropyleneamine oxime; MMSE, mini-mental state examination; SPECT, single photon computed emission tomography; SPM, statistical parametric mapping; UPDRS, unified Parkinson’s disease rating scale
Data processing

Image data were transferred to a personal computer and converted to Analyze format using MRIcro (www.psychology.nottingham.ac.uk/staff/cr1/mricro.html). Data were analysed using SPM99 (http://www.fil.ion.ucl.ac.uk/spm/spm99.html).

A template image was generated by spatially normalising all the HMPAO scans to the generic SPECT template in SPM99. The average of the spatially normalised scans was calculated, and this was used as a template for further spatial normalisation. A region of interest (ROI) encompassing the whole cerebellum was defined from the template image.

For each subject, the repeat HMPAO scan was co-registered with the baseline scan for the same subject using rigid body registration. The baseline scan was then spatially normalised to our template using the standard 12 parameter affine transform, with 7th order polynomial basis functions to account for global non-linear shape differences. The same normalisation parameters were applied to the repeat scan. Images were resliced with a voxel size of 4x4x4 mm. The scans were smoothed with a 10 mm Gaussian. The scan intensity was then normalised by dividing each image by the mean intensity in the cerebellar region of interest (ROI). To determine the change in perfusion, a difference image was calculated by subtracting the spatially and intensity normalised smoothed repeat SPECT scan from the same subject’s baseline scan. This produced for each subject an image in SPM standard space, with the image intensity representing changes over a year in perfusion. We also used an ROI template to calculate, on the intensity and spatially normalised images, the mean perfusion in the temporal, frontal, parietal, and occipital lobes.

Statistical analysis

A mask was generated by thresholding the HMPAO template image with a threshold of 0.5 of the cerebellar intensity. This was used to limit the statistical tests largely to grey matter. The images were statistically analysed using the SPM99 general linear model. One sample t tests were calculated on the images of perfusion change in the Parkinson’s disease and control groups separately to identify regions that showed a significant decrease in perfusion (relative to the

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Demographic factors for the study subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>n</td>
<td>34</td>
</tr>
<tr>
<td>Age (years)</td>
<td>75.7 (6.9)</td>
</tr>
<tr>
<td>Sex, F:M</td>
<td>14:20</td>
</tr>
<tr>
<td>CAMCOG baseline</td>
<td>94.2 (3.8)</td>
</tr>
<tr>
<td>CAMCOG increase</td>
<td>0.2 (0.7)</td>
</tr>
<tr>
<td>CAMCOG executive function baseline</td>
<td>19.9 (4.3)</td>
</tr>
<tr>
<td>CAMCOG executive function increase</td>
<td>0.3 (4.0)</td>
</tr>
<tr>
<td>MMSE baseline</td>
<td>28.2 (1.4)</td>
</tr>
<tr>
<td>MMSE increase</td>
<td>−0.48 (2.2)</td>
</tr>
<tr>
<td>UPDRS baseline</td>
<td>1.1 (1.9)</td>
</tr>
<tr>
<td>UPDRS increase</td>
<td>1.1 (2.0)</td>
</tr>
<tr>
<td>GDS</td>
<td>11 (11)</td>
</tr>
<tr>
<td>Increase in GDS</td>
<td>0.3 (2.4)</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>45 (34)</td>
</tr>
<tr>
<td>Days between HMPAO scans</td>
<td>376 (27)</td>
</tr>
</tbody>
</table>

Values are mean (SD) or n; χ² used for sex, all others unpaired t tests; 62 degrees of freedom (df).

CAMCOG, Cambridge cognitive examination; GDS, geriatric depression scale; HMPAO, hexamethylpropylenamine oxime; MMSE, mini-mental state examination; UPDRS, unified Parkinson’s disease rating scale.

Figure 1 The SPM99 map of cerebral perfusion decrease over one year in the Parkinson’s disease group (thresholded at p < 0.001 uncorrected).

Figure 2 The SPM99 map of lower cerebral perfusion at one year in the Parkinson’s disease group compared with controls (thresholded at p < 0.001 uncorrected).
We hypothesised that parietal perfusion would decrease in the Parkinson's disease group, and that this would correlate with cognitive decline. Although we did not see a significant decline in perfusion in the parietal lobe, neither did the CAMCOG score decrease, which is still consistent with our previous perfusion studies comparing early with late stage Parkinson's disease subjects with Parkinson's disease.

Hypoperfusion in the prefrontal area may reflect disruption or deafferentation of frontostriatal circuitry. We have also shown loss of grey matter in the right dorsolateral cortex in this parkinsonian group, and it is possible that the fronto-parietal regions. These findings are in keeping with previous perfusion studies comparing early with late stage Parkinson's disease, demonstrating that a progressive decrease in cerebral perfusion is a feature of non-demented older subjects with Parkinson's disease.

**Hypoperfusion might also precede or precipitate atrophy.**
hypothesis. This contrasts somewhat with the findings of Tachibana et al., who did find such a correlation, though their subjects were 10 years younger and had a longer duration of disease than ours. It may be that in the present study the time period between the scans was too short for reliable detection of the relatively slow rate of cognitive change in Parkinson’s disease. The CAMCOG test was designed primarily for use in diagnosing dementia and not as a measure of longitudinal change in cognition. Hence it may not have been sensitive enough to detect any cognitive changes present in these groups whose cognition was relatively intact. However, we cannot exclude a drop out effect—that the eight parkinsonian subjects who refused the repeat SPECT scan had a greater degree of cognitive decline than the re-scanned patients.

In conclusion, we have shown decreases in frontal perfusion in Parkinson’s disease over one year. We did not see any cognitive change, but this may have reflected the relatively short time between examinations, or the relative insensitivity of the CAMCOG test. Further longitudinal studies are needed to investigate whether hypoperfusion, either at baseline or over follow up, predicts the development of dementia in Parkinson’s disease. Studies are also needed to investigate the relation between hypoperfusion and dopaminergic receptor systems.

Thanks are due to the patient volunteers for their time, and to Elise Rowan for help with the database. This work was supported by a programme grant from the UK Medical Research Council.

Authors’ affiliations
M J Firbank, I G McKeith, J T O’Brien, The Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
D J Burn, S Molloy, Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne

Competing interests: none declared

Correspondence to: Dr Michael Firbank, Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE, UK; m.j.firbank@ncl.ac.uk

Received 12 November 2004
In revised form 11 February 2005
Accepted 15 February 2005

REFERENCES


Longitudinal change in $^{99m}$TcHMPAO cerebral perfusion SPECT in Parkinson’s disease over one year
M J Firbank, S Molloy, I G McKeith, D J Burn and J T O’Brien

J Neurol Neurosurg Psychiatry 2005 76: 1448-1451
doi: 10.1136/jnnp.2004.058685

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/10/1448

These include:

References
This article cites 22 articles, 12 of which you can access for free at:
http://jnnp.bmj.com/content/76/10/1448#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Stroke (1414)
Brain stem / cerebellum (656)

Notes